Fatal Methotrexate Dosing Error and Ignored Medication Alert
Summary
The deficiency involves the facility’s failure to ensure a resident was free from significant medication errors by not following its Medication Administration policy regarding right dose, right time, and appropriate response to medication alerts. A resident with rheumatoid arthritis was discharged from an acute hospital to the facility with an order for methotrexate 20 mg by mouth every Friday, as documented in the hospital discharge instructions. The resident’s diagnoses included rheumatoid arthritis, shortness of breath, and difficulty walking, and the Minimum Data Set also reflected an active diagnosis of rheumatoid arthritis. Despite this, when the orders were entered into the facility’s system, the Physician’s Order Sheet showed methotrexate 20 mg by mouth every day instead of weekly. When the methotrexate order was entered into the facility’s computer system, a medication alert was generated stating that the order was outside the recommended dose or frequency, specifying that the dosing regimen of 2 tablets daily exceeded the usual dosing regimen of 0.25 mg to 2.5 mg tablets every 7 days and that the daily frequency exceeded the usual weekly frequency. Facility staff interviews indicated that nurses understood medication alerts to mean there was a contraindication or concern requiring contact with the pharmacy or physician to clarify safety, but there was no evidence this alert was acted upon. The Medication Administration Record for November and December showed that the resident received methotrexate 20 mg by mouth daily on multiple dates over several weeks, consistent with the incorrect daily order. The care plan identified methotrexate as a black box warning medication with potential for bone marrow suppression and called for monthly drug regimen review by a pharmacist, yet the pharmacist’s order history and drug regimen review documents showed the methotrexate 20 mg daily order was reviewed on two dates in November with no recommendations and was listed as reviewed without requiring any recommendations. Progress notes documented that in mid-December the resident developed sore throat, difficulty swallowing, epistaxis, lip and chin swelling, and bloody stool. Nursing staff notified the physician, obtained orders including nasal spray, and the resident was sent to the hospital for further evaluation due to ongoing nosebleeds. Hospital emergency documentation recorded that the resident presented with life-threatening cytopenias, critical neutropenia, thrombocytopenia, anemia, acute bleeding, and organ dysfunction, with a diagnosis of methotrexate toxicity with multi-organ involvement and sepsis, and confirmed with the nursing home that the resident had been receiving methotrexate daily, with suspected overdose. The hospital history and physical also documented confirmation from the nursing home that methotrexate was being given daily. The hospital discharge summary described a prolonged course for methotrexate toxicity with severe thrombocytopenia, pancytopenia, septic shock, acute renal failure requiring dialysis, and respiratory failure, after which the resident was transitioned to comfort care and hospice. The death certificate listed acute renal failure, methotrexate toxicity, and rheumatoid arthritis, and stated that the resident ingested a toxic amount of methotrexate. The facility’s Medication Administration policy required medications to be administered as ordered by the physician, in accordance with professional standards, ensuring the six rights including right dosage and right time, use of drug reference material if unfamiliar, special handling of immunosuppressant medications, and reporting and correcting discrepancies, which were not followed in this case. Interviews with facility staff further clarified the actions and inactions leading to the deficiency. The DON stated that the resident was admitted in November and began having swallowing problems and nosebleeds around the middle of December, and that the resident was sent to the hospital due to continued nosebleeds. The DON reported that near the end of December a hospital case manager informed her that the resident appeared to have been receiving methotrexate daily instead of weekly. Upon comparing the facility MAR with the hospital discharge orders, the DON confirmed the resident had been given 20 mg methotrexate daily instead of 20 mg weekly, and that the pharmacy-supplied bubble pack was labeled for daily administration. The nurse who admitted the resident and entered the discharge orders into the facility system stated she entered the orders but could not recall how or why the methotrexate frequency was changed from weekly to daily. The ADON stated that this error could have been caught and was unsure why the system failed. The manufacturer’s black box warning for methotrexate, reviewed by surveyors, emphasized that methotrexate can cause serious, potentially fatal toxic reactions and should only be used by physicians experienced with antimetabolite therapy, underscoring the high-risk nature of the medication that was not properly managed according to facility policy and system alerts.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Significant morphine dose error: An RN administered 0.25 mL (5 mg) of morphine sulfate buccally instead of the ordered 0.1 mL (2 mg) dose to a resident with severe cognitive impairment, Alzheimer’s disease, CAD, and dementia. The RN said she followed the medication box label, while the unit manager confirmed the correct dose was on the EMAR. The resident was assessed afterward and remained unchanged.
An LPN administered Humalog insulin to a resident with stroke, aphasia, and diabetes without priming the insulin pen as required by manufacturer instructions. The LPN dialed the ordered 5-unit dose but did not prime the pen with 2 units before injection, and later stated she was unaware of the need to prime it. The DON confirmed insulin pens should be primed according to the manufacturer's instructions.
A resident with CHF and dysphagia had a medication error when an MA crushed and administered multiple morning meds, including Potassium Chloride ER, despite a provider order that it not be crushed. The facility policy required meds to be given as ordered and prohibited crushing do-not-crush, slow-release, and enteric-coated meds; the record also identified potassium chloride as a high-alert medication.
Two residents experienced significant medication errors when ordered meds were not available or not administered as prescribed. One resident on hospice went more than 24 hours after admission without ordered Morphine for pain and air hunger, while another resident missed multiple doses of a Lidocaine patch and Mirabegron because the meds were out of stock or not obtained from the pharmacy, with the DON confirming the missed doses and unrelieved pain were significant.
A resident with moderately impaired cognition and cerebral amyloid angiopathy had a weekly buprenorphine patch order inaccurately transcribed as Suboxone on the MAR. Staff also applied a new pain patch without removing the old one, leaving two active patches on the resident for several days. The DON stated the admission verification process was not followed and the incident was not investigated.
A resident with DM2 and multiple chronic conditions had an order for daily insulin glargine, but an RN documented that the dose was not given because the medication was unavailable. An LPN stated staff should reorder meds when five doses remain and, if out, notify the provider and pharmacy and use the emergency medication supply system; an RN and the DON confirmed backup insulin was available in a lockbox, and the DON noted there was no documentation explaining the omission.
Significant morphine dose error
Penalty
Summary
The facility failed to ensure a resident was free from a significant medication error when an RN administered 5 mg of morphine sulfate instead of the prescribed 2 mg dose. The resident had severe cognitive impairment and diagnoses that included Alzheimer's disease, coronary artery disease, and dementia. The physician orders directed morphine sulfate concentrate oral solution 100 mg/5 mL to be given as 2 mg (0.1 mL) buccally every four hours for pain, with a separate PRN order for 5 mg (0.25 mL) buccally every hour as needed for breakthrough pain or shortness of breath. The EMAR showed the resident received the scheduled 2 mg dose at 4:00 p.m. and did not show a PRN 5 mg dose. During observation, RN-B withdrew 0.25 mL of morphine sulfate using the syringe provided with the medication and administered it buccally to the resident, then documented on the narcotic record book that 0.1 mL had been given. RN-B stated she gave 0.25 mL because the medication box label identified 0.25 mL, while RN-A stated the correct dose was 0.1 mL and acknowledged the error after RN-B confirmed the amount administered. The resident was assessed after the error and remained unchanged, with vital signs and condition stable. The DON stated the medication label had been followed instead of the EMAR, and the consultant pharmacist stated the resident could have experienced increased drowsiness from the error.
Insulin Pen Not Primed Before Administration
Penalty
Summary
The facility failed to ensure residents were free from significant medication errors when it did not follow insulin pen preparation instructions for Resident #8. Resident #8 was admitted with multiple diagnoses including cerebral infarction (stroke), aphasia, and diabetes, and had a physician order for Humalog (Lispro) insulin pen-injector 100 units/ml to be injected subcutaneously at 5 units before meals for type 2 diabetes. During observation on 8/4/26, an LPN removed the Humalog insulin pen from the medication cart and dialed it to the ordered 5 units, but did not prime the pen with 2 units before administering the dose. The insulin was then given to Resident #8. When interviewed shortly afterward, the LPN stated she did not prime the insulin pen and was unaware of the need to do so before administering insulin. The DON stated insulin pens should be primed according to the manufacturer's instructions and had not been.
Significant medication error involving crushing a do-not-crush ER medication
Penalty
Summary
The facility failed to ensure that a resident was free from significant medication errors when a Medication Aide crushed and administered medications that included Potassium Chloride ER, despite a physician order stating the medication was to be given by mouth twice daily and not crushed. The resident had diagnoses of chronic diastolic heart failure and dysphagia following a cerebral infarction, and the physician’s orders contained no instruction to crush medications. The facility policy stated medications should be administered as ordered and that medications with do-not-crush instructions, including slow release and enteric coated medications, should not be crushed. During observation, the Medication Aide confirmed they were going to crush all of the resident’s morning medications except Pantoprazole. The aide then placed Clopidogrel, Potassium Chloride ER, Sertraline, and Torsemide into a medication cup, crushed them, added pudding, and fed the mixture to the resident. The record review also identified Potassium Chloride as a high alert medication and cited guidance stating that enteric-coated or extended-release tablets or capsules should not be chewed or crushed.
Significant medication errors from delayed and missed ordered medications
Penalty
Summary
The facility failed to obtain physician-ordered medications in a timely manner, resulting in significant medication errors for two residents. One resident was admitted to the facility on 7/9/26 under hospice care with end-stage heart failure and had an order for Morphine Sulfate concentrate 10 mg sublingually every hour as needed for pain and/or air hunger. The resident did not receive Morphine on the day of admission, and the first documented dose was not given until 7/10/26 at 1:41 p.m., about 26 hours after admission. The MAR documented 26 potential missed PRN doses, and the resident’s family member and an LPN stated the medication was not available when needed and that the resident had signs of pain during that period. A second resident had orders for a Lidocaine external patch once daily for mild pain and Mirabegron ER 25 mg daily for urinary antispasmodic use. The MAR and nursing notes documented that the Lidocaine patch was not administered for multiple days because it was out of stock, with missed applications documented on 7/26, 7/27, 7/29, and 7/30, and 7/28 signed in error as given. The resident stated the missed patches prevented comfortable sleep. The same resident also missed Mirabegron doses on multiple days because the medication was on order from the pharmacy and not available, with documentation showing missed administration on 7/14, 7/15, 7/16, 7/17, 7/19, 7/20, and 7/21, and one date documented as given in error. The DON confirmed the Lidocaine order did not include a dose and acknowledged the resident missed several doses because the facility ran out of the patches. The DON also confirmed the Mirabegron was not supplied as expected and that the convenience box did not contain that medication. The resident and family member stated the missed medications affected pain control, sleep, and urinary urgency, and the DON stated the quantity of missed doses and unrelieved pain equated to significant medication errors.
Medication Order Transcription Error and Duplicate Pain Patch Application
Penalty
Summary
The facility failed to ensure a resident remained free from significant medication errors when admission medication orders were not accurately transcribed to the MAR. The resident was admitted with diagnoses including cerebral amyloid angiopathy, and the comprehensive assessment showed moderately impaired cognition and a need for assistance from one staff member with ADLs. The hospital discharge orders included a weekly buprenorphine transdermal patch, but the July 2026 MAR listed the medication as a weekly Suboxone transdermal patch instead. Staff later stated the wrong medication name was entered because Suboxone was believed to be the same medication as buprenorphine, and the admission body check was not completed to determine whether a transdermal patch was already present. The resident representative reported that facility staff applied a new pain patch without removing the old one, leaving two active patches on the resident for three days. Staff later confirmed one patch was on the right shoulder and another on the left shoulder, and the older patch was then removed. The DON stated the facility’s medication error process included staff interviews, physician notification, alert charting, and monitoring for high-alert medications, but also stated the incident was not investigated and no medication error report was completed. The DON further stated the admission process required a three-step verification of orders, and that process was not followed for this resident.
Missed Insulin Dose Due to Medication Unavailability
Penalty
Summary
A resident with type 2 diabetes mellitus, chronic diastolic heart failure, chronic respiratory failure, and obesity had a physician order for Insulin Glargine Solostar 300 units/mL, 50 units subcutaneously once daily. On 3/20/26 at 11:19 AM, an RN documented that the insulin was not administered because the medication was unavailable. During interviews on 7/30/26, an LPN stated that medications should be reordered through the eMAR when five doses remain and that if a medication is completely out, staff must immediately notify the provider and pharmacy and use the emergency medication supply system. An RN confirmed that backup insulin was available in a lockbox in the third-floor refrigerator and that staff should not run out of insulin. The DON also confirmed the backup insulin location and the pharmacy restocking alert system, and stated there was no documentation in the progress notes or TAR explaining the omission; because she was not employed at the facility at the time, the exact reason for the unavailable medication and omitted dose remained unknown.
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release October 8, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.